Alkermes plc (NASDAQ:ALKS) reported its past quarter results on 02/25/2016

Alkermes plc (NASDAQ:ALKS) moved up 27.83% and closed its last trading session at $55.62. This Medical Sector stock currently has the Market Capitalization of 6.59 Billion. The Average Volume for the stock is measured as 795.81 Million. The Stock has a 52-Week High of $80.71 and 52-Week Low of $27.14 following the dates, it touched its 52-Week High on Dec 29, 2015 and 52-Week Low on Mar 17, 2016. Currently, the Return on Assets value for the trailing twelve months is -15% with the Return on Equity and Return on Investment of -21.2% and -13.7% respectively. This firm currently has YTD (year to date) performance of -29.93 Percent which is not good. The Short Ratio for the stock is 5.36.

Alkermes plc (NASDAQ:ALKS) Price to Earnings (P/E) ratio is 0. EPS or Earning per Share stands at $-1.83. The TTM operating margin is -40.2 percent.

Alkermes plc (NASDAQ:ALKS) is due to report its Earnings on Thu 3 Nov (In 11 Days). The estimated EPS for the current quarter is said to be $-0.25. Following Earnings result, share price were UP 14 times out of last 27 Qtrs. The stock has added about 7.4% since it reported its last earnings. The Closing price of Alkermes plc (NASDAQ:ALKS) at Last Earnings was $51.78 as compared to the previous closing price of $43.51. The Predicted Move on the 7th day after Alkermes plc (NASDAQ:ALKS) will release its earnings at about 6%.

By Looking at Earnings History, Out of 12 Quarters when the Earnings were reported, Alkermes plc (NASDAQ:ALKS) beats earnings by 50%, The Stock Missed Earnings  6  times and has met earnings  0 times.

Earnings History:

We will discuss the past Quarters Earnings below:

Alkermes plc (NASDAQ:ALKS) reported its previous quarter on 07/28/2016 where it reported the Actual Earnings of $-0.01. The Closing price before the company posted its earnings was $51.78. The Stock declined on the very next day of earnings and maintained its stock price at $48.13 by showing a % change of -7.05 percent from its previous closing price. The Next Day Volume after Earnings was reported as 1.71 Million. On the 7th day After Earnings Report, the stock hit its share price as $49.55 by showing -4.31% decrease from the Stock price Before Earnings were reported.

On 04/28/2016, the stock reported the EPS of $-0.12 where Analysts were projecting the EPS to be $-0.21 showing a difference of $0.09. Thus Surprise Factor was there with 42.9 percent. Before Earnings Announcement on 04/28/2016, the firm had its stock price of $40.57. And immediately on the next day after earnings announcement, the stock inclined 1.77% and closed its trading session at $41.29. On 7th Day after earnings release, Alkermes plc (NASDAQ:ALKS) dropped to -7.27% from $40.57 to $37.62.

On 02/25/2016, Analysts were suspecting EPS of $-0.18/share where Alkermes plc (NASDAQ:ALKS) reported its Actual EPS of $-0.14. Thus showing a Surprise of 22.2 percent. The Closing Price of the stock before earnings was $34.07 while on the Next day the stock closed its trading session at $33.97 with a percentage change of -0.29% from the price of 34.07 before Earnings. The Stock Closing Price on the 7th day of earnings was $35.19.

Company Profile:

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide. The company’s marketed products include ARISTADA (aripiprazole lauroxil) for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; INVEGA TRINZA for the treatment of schizophrenia used in people who have been treated with INVEGA SUSTENNA; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to improve walking in adults with multiple sclerosis who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) for the treatment of type 2 diabetes. It is also developing ALKS 5461 that is in a Phase III study for the treatment of major depressive disorder; ALKS 3831, which is in a Phase II study to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is in a Phase I study to treat multiple sclerosis; ALKS 6428, which is in a phase III study to help physicians transition patients from physical dependence on opioids to antagonist therapy; Aripiprazole lauroxil, an injectable atypical antipsychotic, which has completed a Phase I study for the treatment of schizophrenia; ALKS 7119 that is in a Phase I study for the treatment of various central nervous system diseases; RDB 1450, a proprietary investigational biologic cancer immunotherapy product that is in pre-clinical stage. The company serves pharmaceutical wholesalers, and specialty pharmacies and distributors. It has collaboration agreements with Janssen Pharmaceutica N.V.; AstraZeneca plc; and Acorda Therapeutics, Inc. Alkermes Public Limited Company was founded in 1987 and is headquartered in Dublin, Ireland.